1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study.

Leavy, OC; Russell, RJORCID logo; Harrison, EM; Lone, NIORCID logo; Kerr, S; Docherty, AB; Sheikh, A; Richardson, M; Elneima, OORCID logo; Greening, NJORCID logo; +63 more...Harris, VC; Houchen-Wolloff, L; McAuley, HJORCID logo; Saunders, RM; Sereno, M; Shikotra, A; Singapuri, A; Aul, R; Beirne, P; Bolton, CEORCID logo; Brown, JS; Choudhury, G; Diar Bakerly, N; Easom, N; Echevarria, C; Fuld, J; Hart, NORCID logo; Hurst, JRORCID logo; Jones, MORCID logo; Parekh, DORCID logo; Pfeffer, P; Rahman, NM; Rowland-Jones, S; Shah, AM; Wootton, DG; Jolley, CORCID logo; Thompson, ARORCID logo; Chalder, T; Davies, MJ; De Soyza, AORCID logo; Geddes, JR; Greenhalf, W; Heller, S; Howard, LORCID logo; Jacob, JORCID logo; Jenkins, RG; Lord, JM; Man, WDORCID logo; McCann, GP; Neubauer, S; Openshaw, PJORCID logo; Porter, JORCID logo; Rowland, MJ; Scott, JT; Semple, MGORCID logo; Singh, SJORCID logo; Thomas, D; Toshner, MORCID logo; Lewis, K; Heaney, LG; Briggs, AORCID logo; Zheng, B; Thorpe, M; Quint, JKORCID logo; Chalmers, JD; Ho, L; Horsley, AORCID logo; Marks, MORCID logo; Poinasamy, K; Raman, BORCID logo; Wain, LVORCID logo; Brightling, CE; Evans, RAORCID logo and (2024) 1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study. ERJ open research, 10 (5). 00474-2024. ISSN 2312-0541 DOI: 10.1183/23120541.00474-2024
Copy

BACKGROUND: In patients with coronavirus disease 2019 (COVID-19) requiring supplemental oxygen, dexamethasone reduces acute severity and improves survival, but longer-term effects are unknown. We hypothesised that systemic corticosteroid administration during acute COVID-19 would be associated with improved health-related quality of life (HRQoL) 1 year after discharge. METHODS: Adults admitted to hospital between February 2020 and March 2021 for COVID-19 and meeting current guideline recommendations for dexamethasone treatment were included using two prospective UK cohort studies (Post-hospitalisation COVID-19 and the International Severe Acute Respiratory and emerging Infection Consortium). HRQoL, assessed by the EuroQol-Five Dimensions-Five Levels utility index (EQ-5D-5L UI), pre-hospital and 1 year after discharge were compared between those receiving corticosteroids or not after propensity weighting for treatment. Secondary outcomes included patient-reported recovery, physical and mental health status, and measures of organ impairment. Sensitivity analyses were undertaken to account for survival and selection bias. FINDINGS: Of the 1888 participants included in the primary analysis, 1149 received corticosteroids. There was no between-group difference in EQ-5D-5L UI at 1 year (mean difference 0.004, 95% CI -0.026-0.034). A similar reduction in EQ-5D-5L UI was seen at 1 year between corticosteroid exposed and nonexposed groups (mean±sd change -0.12±0.22 versus -0.11±0.22). Overall, there were no differences in secondary outcome measures. After sensitivity analyses modelled using a cohort of 109 318 patients admitted to hospital with COVID-19, EQ-5D-5L UI at 1 year remained similar between the two groups. INTERPRETATION: Systemic corticosteroids for acute COVID-19 have no impact on the large reduction in HRQoL 1 year after hospital discharge. Treatments to address the persistent reduction in HRQoL are urgently needed.


picture_as_pdf
Leavy-et-al-2024-1-year-health-outcomes-associated-with-systemic-corticosteroids-for-covid-19.pdf
subject
Published Version
Available under Creative Commons: Attribution 4.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads